tocopherol propyl ether | 63043-88-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: tocopherol propyl ether
• 英文别名: 2,5,7,8-Tetramethyl-6-propoxy-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromene
• CAS: 63043-88-9
• 化学式: C₃₂H₅₆O₂
• 分子量: 472.795
• InChiKey: MYUPNPLCXPDZQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.9
• 重原子数：
  34
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND
  申请人：Schroeder Rudolf

  公开号：US20090143423A1

  公开（公告）日：2009-06-04

  A solid dispersion product comprising at least one N-aryl urea-based pharmaceutically active agent or an agent of related structural type is obtained by a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix-forming agent, at least one pharmaceutically acceptable surfactant and at least one solvent, and b) removing the solvent(s) from the liquid mixture to obtain the solid dispersion product.

  通过a)制备含有至少一种N-芳基脲基药物活性剂或相关结构类型的药剂学活性剂的固体分散产品，包括制备液体混合物，其中包含至少一种活性剂、至少一种药学上可接受的基质形成剂、至少一种药学上可接受的表面活性剂和至少一种溶剂，然后b)从液体混合物中去除溶剂，以获得固体分散物。
• PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR
  申请人：Liepold Bernd

  公开号：US20100143459A1

  公开（公告）日：2010-06-10

  A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.
• FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER
  申请人：Catron Nathaniel

  公开号：US20100297194A1

  公开（公告）日：2010-11-25

  An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
• PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR
  申请人：Packhaeuser Claudia

  公开号：US20100310648A1

  公开（公告）日：2010-12-09

  The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.
• PHARMACEUTICAL DOSAGE FORM COMPRISING POLYMERIC CARRIER COMPOSITION
  申请人：Liepold Bernd

  公开号：US20110182891A1

  公开（公告）日：2011-07-28

  A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.